Results 81 to 90 of about 1,466,333 (379)

CDR loop interactions can determine heavy and light chain pairing preferences in bispecific antibodies

mAbs, 2022
As the current biotherapeutic market is dominated by antibodies, the design of different antibody formats, like bispecific antibodies, is critical to the advancement of the field.
Monica L. Fernández-Quintero, Katharina B. Kroell, Lukas J. Grunewald, Anna-Lena M. Fischer, Jakob R. Riccabona, Klaus R. Liedl   +5 more
doaj   +1 more source

A PSMA-targeted bispecific antibody for prostate cancer driven by a small-molecule targeting ligand

Science Advances, 2021
CCW702 is a bispecific antibody that combines the specificity of an imaging ligand with the potency of a T cell immunotherapy. Despite the development of next-generation antiandrogens, metastatic castration-resistant prostate cancer (mCRPC) remains ...
S. C. Lee, Jennifer S. Y. Ma, Min Soo Kim, Eduardo Laborda, Sei-hyun Choi, Eric N. Hampton, Hwayoung Yun, V. Núñez, Michelle Muldong, Christina N. Wu, Wenxue Ma, A. Kulidjian, C. Kane, V. Klyushnichenko, A. Woods, S. Joseph, M. Petrassi, J. Wisler, Jing Li, C. Jamieson, P. Schultz, Chan Hyuk Kim, T. Young   +22 more
semanticscholar   +1 more source

Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment

Experimental Hematology & Oncology, 2017
HER2-targeted immunotherapy consists of monoclonal antibodies (e.g. trastuzumab, pertuzumab), bispecific antibodies (e.g. MM-111, ertumaxomab) and activated T cells armed with anti-HER2 bispecific antibody (HER2Bi-aATC). Trastuzumab is a classic drug for
Shengnan Yu, Qian Liu, Xinwei Han, Shuang Qin, Weiheng Zhao, Anping Li, Kongming Wu   +6 more
doaj   +1 more source

Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. [PDF]

PLoS ONE, 2013
In hemophilia A, routine prophylaxis with exogenous factor VIII (FVIII) requires frequent intravenous injections and can lead to the development of anti-FVIII alloantibodies (FVIII inhibitors).
Zenjiro Sampei, Tomoyuki Igawa, Tetsuhiro Soeda, Yukiko Okuyama-Nishida, Chifumi Moriyama, Tetsuya Wakabayashi, Eriko Tanaka, Atsushi Muto, Tetsuo Kojima, Takehisa Kitazawa, Kazutaka Yoshihashi, Aya Harada, Miho Funaki, Kenta Haraya, Tatsuhiko Tachibana, Sachiyo Suzuki, Keiko Esaki, Yoshiaki Nabuchi, Kunihiro Hattori   +18 more
doaj   +1 more source

Microphysiological Systems for Comorbidity Studies: Chronic Kidney Disease and Osteoarthritis

Advanced Healthcare Materials, EarlyView.
This review highlights the potential of organ‐on‐a‐chip systems for studying comorbidities, using chronic kidney disease (CKD) and osteoarthritis (OA) as examples. It summarizes recent advances in kidney‐on‐a‐chip and joint‐on‐a‐chip models and discusses their current and potential application in investigating CKD, OA, and CKD‐OA comorbidity, aiming to
Mingying Han, Weiping Lin, Yuanxiong Cao, Patricia Murray, Bettina Wilm, Stephen J McWilliam, Jude Curran, Ruoxiao Xie   +7 more
wiley   +1 more source

Nanoparticle‐Mediated Targeted Protein Degradation: An Emerging Therapeutics Technology

Angewandte Chemie, EarlyView.
Targeted protein degradation (TPD) has emerged as a powerful therapeutic approach, with numerous candidates molecules now advancing into clinical development. Recent innovations have incorporated nanoparticles to facilitate and enhance these degradation processes, yielding synergistic effects.
Andrew G. Baker, Adrian Pui Ting Ho, Laura S. Itzhaki, Ljiljana Fruk   +3 more
wiley   +2 more sources

CLEC5a-directed bispecific antibody for effective cellular phagocytosis

mAbs, 2022
While antibody-dependent cellular phagocytosis mediated by activating Fcγ receptor is a key mechanism underlying many antibody drugs, their full therapeutic activities can be restricted by the inhibitory Fcγ receptor IIB (FcγRIIB).
Vivekananda Kedage, Diego Ellerman, Mingjian Fei, Wei-Ching Liang, Gu Zhang, Eric Cheng, Juan Zhang, Yongmei Chen, Haochu Huang, Wyne P. Lee, Yan Wu, Minhong Yan   +11 more
doaj   +1 more source

Treatment of Adult Patients with Relapsed/Refractory B-Cell Philadelphia-Negative Acute Lymphoblastic Leukemia [PDF]

, 2019
The majority of adult patients affected by B-cell acute lymphoblastic leukemia (B-ALL) will relapse after an initial response, while approximately 20% will display primary resistant disease. Patients suffering from relapsed/refractory B-ALL have a very
Lanza, Francesco, Maffini, Enrico, Saraceni, Francesco   +2 more
core   +1 more source

Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling

npj Systems Biology and Applications, 2020
Mosunetuzumab, a T-cell dependent bispecific antibody that binds CD3 and CD20 to drive T-cell mediated B-cell killing, is currently being tested in non-Hodgkin lymphoma.
I. Hosseini, K. Gadkar, E. Stefanich, Chi-Chung Li, L. Sun, Y. Chu, S. Ramanujan   +6 more
semanticscholar   +1 more source

Recent Advances in mRNA Delivery Systems for Cancer Therapy

Advanced Science, EarlyView.
This review systematically investigates the applications of mRNA therapy in cancer treatment, with particular emphasis on nonviral delivery systems, targeting strategies, stimulus‐responsive systems, and local delivery methods. Concluding with a meticulous evaluation, the review sheds light on the prevailing challenges while illuminating promising ...
Zheng Zhang, Ya‐Nan Fan, Si‐Qi Jiang, Ya‐Jing Ma, Yao‐Ru Yu, Yu‐Xin Qing, Qian‐Ru Li, Yi‐Lin Liu, Song Shen, Jun Wang   +9 more
wiley   +1 more source